Recarbrio
Chemical Name | imipenem, cilastatin, and relebactam |
Dosage Form | Injectable (intravenous; 1.25 g/vial) |
Drug Class | Inhibitors |
System | Urinary, Digestive |
Company | Merck & Co. |
Approval Year | 2019 |
Indication
- Recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections.